Filtered By:
Condition: Diabetes
Countries: Norway Health

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 39 results found since Jan 2013.

Dapagliflozin Compared to DPP ‐4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All‐cause Mortality in Type 2 Diabetes Patients (CVD‐REAL Nordic): a multinational observational study
ConclusionsDapagliflozin was associated with lower risks of cardiovascular events and all‐cause mortality compared to DPP‐4i in a in a real‐world clinical setting and broad T2D population.
Source: Diabetes, Obesity and Metabolism - August 1, 2017 Category: Endocrinology Authors: F Persson, T Nystr öm, M E Jørgensen, B Carstensen, H L Gulseth, M Thuresson, P Fenici, D Nathanson, J W Eriksson, A Norhammar, J Bodegard, K I Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Dapagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
ConclusionsDapagliflozin was associated with lower risks of CV events and all‐cause mortality compared with DPP‐4 inhibitors in a real‐world clinical setting and a broad T2D population.
Source: Diabetes, Obesity and Metabolism - September 8, 2017 Category: Endocrinology Authors: Frederik Persson, Thomas Nystr öm, Marit E. Jørgensen, Bendix Carstensen, Hanne L. Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W. Eriksson, Anna Norhammar, Johan Bodegard, Kåre I. Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Long-Term Exposure to Transportation Noise in Relation to Development of Obesity —a Cohort Study
Conclusion: Our results link transportation noise exposure to development of obesity and suggest that combined exposure from different sources may be particularly harmful. https://doi.org/10.1289/EHP1910 Received: 17 March 2017 Revised: 5 October 2017 Accepted: 9 October 2017 Published: 20 November 2017 Address correspondence to A. Pyko, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden. Telephone: 46(0) 852487561. Email: Andrei.pyko@ki.se Supplemental Material is available online (https://doi.org/10.1289/EHP1910). The authors declare they have no actual or potential competing fina...
Source: EHP Research - November 20, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research

Burden of disease due to transportation noise in the Nordic countries
CONCLUSION: Further harmonization of noise exposure data is required for between-country comparisons. Moreover, nationwide noise models indicate that DALY estimates based on END considerably underestimate national BoD due to transportation noise. The health-related burden of traffic noise was comparable to that of air pollution, an established risk factor for disease in the GBD framework. Inclusion of environmental noise as a risk factor in the GBD is strongly encouraged.PMID:37156356 | DOI:10.1016/j.envres.2023.116077
Source: Environmental Research - May 8, 2023 Category: Environmental Health Authors: Gunn Marit Aasvang Leo Stockfelt Mette S ørensen Anu W Turunen Nina Roswall Tarja Yli-Tuomi Mikael Ögren Timo Lanki Jenny Selander Natalia Vincens Andrei Pyko G öran Pershagen Gerhard Sulo Anette Kocbach B ølling Source Type: research

Prevalence, incidence and remission of urinary incontinence in women: longitudinal data from the Norwegian HUNT study (EPINCONT)
Conclusion: Crude UI prevalence increased between the studies. Changes in known risk factors for UI such as age, BMI, weight and parity could explain some of the relative increase in prevalence, and were also found to be associated with either incidence of UI, remission of UI or both.
Source: BMC Urology - Latest articles - May 30, 2013 Category: Urology & Nephrology Authors: Marit EbbesenSteinar HunskaarGuri RortveitYngvild Hannestad Source Type: research

Diabetes severity and the role of leisure time physical exercise on cardiovascular mortality: the Nord-Trlatin small letter o with strokendelag Health study (HUNT), Norway
Conclusions: The data suggest a more favourable effect of exercise in people with diabetes who used medication than in those who did not, suggesting that physical exercise should be encouraged as a therapeutic measure additional to medical treatment.
Source: Cardiovascular Diabetology - June 6, 2013 Category: Cardiology Authors: Børge MoeLiv Berit AugestadTom Nilsen Source Type: research

Nanomaterials Versus Ambient Ultrafine Particles: An Opportunity to Exchange Toxicology Knowledge
Conclusion: There is now an opportunity to apply knowledge from NM toxicology and use it to better inform PM health risk research and vice versa. https://doi.org/10.1289/EHP424 Received: 17 December 2015 Revised: 12 August 2016 Accepted: 30 August 2016 Published: 10 October 2017 Address correspondence to V. Stone, School of Life Sciences, Heriot-Watt University, Edinburgh, UK. Telephone: +44 131 451 3460. Email: v.stone@hw.ac.uk V.S. currently receives grant funding from Byk Altana and from The European Ceramic Fibre Industry Association (ECFIA). In the past, V.S. has received funding from Unilever and GlaxoSmithKline....
Source: EHP Research - October 10, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Review Source Type: research

Can we go beyond surrogates?
Two years ago, data presented at the annual American Diabetes Association (ADA) meeting in New Orleans showed a marked decrease in deaths, especially those due to cardiovascular disease, with the use of empagliflozin. Two major questions have been asked: (i) was the result a fluke; and (ii) was it a class effect, or was it specific to the agent used? The hope that both questions would be answered by a second study has been answered: the conclusions of EMPA‐REG were not an anomaly and it is a class effect, not one caused by a specific drug. Importantly, do these studies require us to alter our algorithms for the treatment...
Source: Journal of Diabetes - October 19, 2017 Category: Endocrinology Authors: Andrew Drexler Tags: Editorial Source Type: research